CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is recorded as a service provider in 37 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 37 trials · Latest update first
Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
Sponsor Liquidia Technologies Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin Versus Sapropterin in Participants With Phenylketonuria ≥2 Years of Age
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 82 enrolled participants tested for sepiapterin responsiveness in Part 1, 62 were randomized for Part 2; 15 were nonresponders and 5 did not meet Part 1 eligibility criteria.
- Protocol amendments modified eligibility criteria, ultimately specifying exclusion of incapacitated adults, and clarified the primary analysis set and efficacy-endpoint analyses.
- Protocol amendments clarified Part 1 and Part 2 washout periods, dietary-control observation duration, and added a +1-day window for virtual visits.
- Enrollment of participants with biochemically diagnosed classical PKU was capped at 30% of the safety analysis set.
These findings describe the trial, not the service provider’s performance or responsibility.
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND / 299AR301)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo HCT)
Sponsor Symbio Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich Ataxia
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Sponsor Avalyn Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Sponsor Quell Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
Sponsor Travere Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin (EPIPHENY)
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)
Sponsor Maze Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
Sponsor Nefro Avillion Clinical Development LLC
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058) Administered Subcutaneously in Subjects with Cystathionine Beta-Synthase-Deficient Homocystinuria (COMPOSE)
Sponsor Travere Therapeutics Switzerland GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients with Danon Disease
Sponsor Rocket Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma
Sponsor ADCendo ApS
- Start (EU)
- Latest update
- Estimated end
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare
Sponsor Olatec Therapeutics LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for CTI Clinical Trial and Consulting Services?
The 2026-10-09 snapshot links CTI Clinical Trial and Consulting Services to 37 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Data management, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for CTI Clinical Trial and Consulting Services?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Transplantation, Metabolic Disorders, Nephrology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to CTI Clinical Trial and Consulting Services conducted?
The linked trials record locations in 21 countries, including Germany, France, Spain, Italy, Czechia. These are trial locations, not confirmed office locations or countries where CTI Clinical Trial and Consulting Services delivered services.
What can this page tell me about CTI Clinical Trial and Consulting Services's trial experience?
Browse 37 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 4 recorded name variants under CTI Clinical Trial and Consulting Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CTI Clinical Trial And Consulting Services Europe GmbH
- CTI Clinical Trial And Consulting Services Inc.
- CTI Clinical Trial And Consulting Services Portugal Unipessoal Lda.
- CTI Clinical Trial and Consulting Services Europe GmbH